StockNews.com started coverage on shares of Oragenics (NYSE:OGEN – Get Rating) in a report issued on Monday morning. The firm issued a sell rating on the stock.
Oragenics Stock Performance
Shares of NYSE OGEN opened at $3.31 on Monday. The stock has a market cap of $6.49 million, a PE ratio of -0.43 and a beta of 0.37. Oragenics has a 12-month low of $2.61 and a 12-month high of $24.00.
Get Oragenics alerts:Oragenics Company Profile
(Get Rating)
Oragenics Inc is a biotechnology company focused on the development and licensure of innovative products and technologies for improving human health.
Further Reading
- Get a free copy of the StockNews.com research report on Oragenics (OGEN)
- ASML Reports Massive Growth, Management Points To Sluggish 2023
- Will Analyst Boost Send Lockheed Martin Shares Up, Up and Away?
- Mullen Automotive: Is The Bloom Off The Rose?
- Diversified Abbott Laboratories Could Reverse And Move Higher
- Okta Reversal In Progress While Catalysts Approach
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.